By Connor Hart
Artiva Biotherapeutics named Subhashis Banerjee as its chief medical officer, succeeding Thorsten Graef, who will continue to serve the company as a strategic adviser.
Banerjee is a trained rheumatologist and immunologist with more than two decades of clinical development experience in autoimmune diseases, the San Diego-based company said Tuesday.
His appointment will help the company progress the clinical development of its treatment of B-cell driven autoimmune diseases, Chief Executive Fred Aslan said.
Prior to joining Artiva, Banerjee helmed Bristol Myers Squibb's rheumatology and dermatology global development arm. Previously, he held an executive position at Vyne Therapeutics.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
April 08, 2025 16:57 ET (20:57 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。